Last reviewed · How we verify
Severe myoclonic epilepsy in infancy
Approved treatments
- Epidiolex · Jazz Pharms Res
Epidiolex works by inhibiting the activity of caspase-1, a protein involved in the inflammatory response and neuronal excitability. - Epidiolex · Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Severe myoclonic epilepsy in infancy patent landscape — cliff calendar, originator estates, attackable patents
- Severe myoclonic epilepsy in infancy treatment landscape brief
- Severe myoclonic epilepsy in infancy treatment updates RSS
Frequently asked questions about Severe myoclonic epilepsy in infancy
What drugs treat Severe myoclonic epilepsy in infancy?
Tracked treatments include Epidiolex.
What is the treatment for Severe myoclonic epilepsy in infancy?
Standard treatment for Severe myoclonic epilepsy in infancy includes Epidiolex. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Severe myoclonic epilepsy in infancy patent cliff · Severe myoclonic epilepsy in infancy CI report
- Treatment: Epidiolex · Jazz Pharms Res
- Treatment: Epidiolex · Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing